MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology Congress
11 oct. 2023 10h15 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics presents positive 12-week data from the Phase 2 MIRA trial with Nanobody® Sonelokimab for Hidradenitis Suppurativa at the European Academy of Dermatology and Venereology...
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology and Venereology Congress
04 oct. 2023 07h01 HE
|
MoonLake Immunotherapeutics AG
Phase 2 MIRA primary analysis trial results (12-week) for MoonLake’s Nanobody® sonelokimab in hidradenitis suppurativa to be presented at a late-breaking session at the European Academy of Dermatology...
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11
06 sept. 2023 07h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics to host a Capital Markets Day on Monday, September 11 ZUG, Switzerland, September 6, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage...
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and Provides a Business Update
10 août 2023 07h00 HE
|
MoonLake Immunotherapeutics AG
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS), suggesting that, as early as week 12, the Nanobody® sonelokimab, relative to placebo,...
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
25 juil. 2023 08h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readoutsRandomization target of 200 patients...
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares
28 juin 2023 05h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Pricing of $400 Million Upsized Public Offering of Class A Ordinary Shares ZUG, Switzerland, June 28, 2023 – MoonLake Immunotherapeutics (Nasdaq:MLTX)...
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering
26 juin 2023 16h01 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Announces Proposed Underwritten Public Offering ZUG, Switzerland, June 26, 2023 – MoonLake Immunotherapeutics (NASDAQ:MLTX) (“MoonLake”), a clinical-stage biotechnology...
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa
25 juin 2023 09h00 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics achieves landmark milestone with positive Phase 2 results for Nanobody® sonelokimab in hidradenitis suppurativa First placebo-controlled randomized trial in HS to report...
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update
12 mai 2023 07h45 HE
|
MoonLake Immunotherapeutics AG
MoonLake Immunotherapeutics Reports First Quarter 2023 Financial Results and Provides a Business Update Capital Markets Day held in April highlighted the differentiating features of sonelokimab and...
MoonLake Immunotherapeutics and SHL Medical collaborate to jointly develop an autoinjector for sonelokimab supply
03 mai 2023 06h45 HE
|
MoonLake Immunotherapeutics AG
ZUG, Switzerland, May 3, 2023 – MoonLake Immunotherapeutics (NASDAQ: MLTX) (“MoonLake”), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases,...